Post-earnings recap
Reported
Tue, May 4, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Protagonist Therapeutics reported a narrower-than-expected loss per share, which contributed to a slight increase in stock price. Investors reacted positively to the management's comments on clinical trial progress, despite the lack of revenue data and future guidance. The stock's modest gain reflects cautious optimism among investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.54 | N/A | +4.93% |
| Revenue | N/A | N/A | N/A |
Management expressed optimism about ongoing projects and their potential impact. However, they did not offer specific guidance for the upcoming quarters.
Management highlighted progress in their clinical trials.
They emphasized their commitment to advancing their pipeline.
No specific guidance was provided for future quarters.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—